Proactive Investors

Proactiveinvestors is a prominent multimedia news company, an investor platform, and an events management firm, with locations in New York, Sydney, Toronto, Frankfurt, and London. This organization runs five financial websites in four different languages, delivering up-to-the-minute news, insights, and analysis on numerous publicly traded companies worldwide every day. We are among the fastest-growing financial media platforms globally. Additionally, Proactiveinvestors hosts highly successful "investor forums," where three to four companies showcase their offerings to a select audience of affluent investors, fund managers, hedge funds, private client brokers, and analysts.

International, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#340795

United States

#220315

Finance/Investing

#2149

Traffic sources

Monthly visitors

Articles

Aldeyra Therapeutics tanks as FDA rejects investigational dry eye disease therapy

2 weeks ago | proactiveinvestors.com | Emily Jarvie |Angela Harmantas

About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022.
Genflow Biosciences CEO welcomes new investment; outlines dog longevity trial | LSE:GENF, OTCQB:GENFF

4 weeks ago | proactiveinvestors.com

Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about a pivotal new direction for the company as...
Nasdaq closes in correction territory as tech sell-off sends Wall Street tumbling

1 month ago | proactiveinvestors.com | Oliver Haill |Emily Jarvie

About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research.
US Global Investors CEO discusses ETF growth potential amid 2025 travel boom - ICYMI

1 month ago | proactiveinvestors.com | Emily Jarvie

U.S. Global Investors (NASDAQ:GROW) CEO Frank Holmes talked with Proactive about the growing travel sector, highlighting the performance of Trip ETF and Jets ETF, and the impact of AI on travel pricing. Holmes explained that Trip ETF, listed on the London Stock Exchange, offers broader exposure to hotels, cruise lines, and the hospitality sector, while Jets ETF remains focused on airlines and is listed on the New York Stock Exchange. Proactive: All right.
Century Lithium details savings opportunities at Angel Island project - ICYMI

1 month ago | proactiveinvestors.com | Emily Jarvie

Century Lithium Corp. (TSX-V:LCE, OTCQX:CYDVF) chief financial officer Braam Jonker joined Proactive to discuss the latest developments at the company’s Angel Island lithium project in Nevada. The company has completed an optimization study, highlighting how the company expects to reduce capital expenditure (CapEx) by up to 25% during Phase 1 of the project. Proactive: Welcome back inside our Proactive newsroom. Joining me now is Braam Jonker, chief financial officer for Century Lithium.
TNR Gold eyes first royalty payment from Gangfeng Lithium’s Mariana project - ICYMI

1 month ago | proactiveinvestors.com | Emily Jarvie

TNR Gold Corp (TSX-V:TNR, OTC:TRRXF) executive chairman Kirill Klip talked with Proactive about the latest developments at Ganfeng’s Mariana lithium project in Argentina. With production now underway, TNR Gold is set to start receiving royalty cash payments, marking a significant shift for the company. Proactive: Hello, you're watching Proactive. I'm joined by TNR Gold Executive Chairman Kirill Klip.
Candel Therapeutics CEO discusses promising Phase 2 pancreatic cancer trial results - ICYMI

1 month ago | proactiveinvestors.com | Emily Jarvie

Candel Therapeutics Inc (NASDAQ:CADL) CEO Dr Paul Peter Tak talked with Proactive about the encouraging results from the phase 2 trial of its investigational medicine CAN-2409 for borderline resectable pancreatic cancer. Dr Tak shared that the median overall survival in the active treatment group reached 31.4 months, compared to just 12.5 months in the control group, showing a clear separation of survival curves.
Frank Talk: Is it time for the US to revalue its gold reserves?

1 month ago | proactiveinvestors.com | Angela Harmantas

Gold has long been a cornerstone of global finance, prized for its stability in times of uncertainty. But last week, the precious metal made history, soaring to an all-time high of $2,940 per ounce and pushing its total market value past $20 trillion for the first time ever. While safe-haven demand has fueled much of this surge, another potential catalyst is emerging—one that could send prices even higher: the revaluation of America's vast gold reserves.
Nano One Materials increases financial flexibility through Quebec site sale - ICYMI

1 month ago | proactiveinvestors.com | Emily Jarvie

Nano One Materials Corp (TSX:NANO, OTC:NNOMF) this week announced the strategic sale of its Quebec facility for more than $20 million, delivering more than two times the initial $10.25 million investment. Chief operating officer Alex Holmes joined Proactive to discuss the development, which aligns with Nano One's capital-light business model. Proactive: All right. Welcome back inside our proactive newsroom. And joining me now is Alex Holmes.
Biotechs challenge big pharma with new oral weight loss therapies

1 month ago | proactiveinvestors.com | Emily Jarvie |Angela Harmantas

With the smash success of glucagon-like peptide-1 (GLP-1) agonists as a treatment for obesity, pharmaceutical giants and emerging biotechnology firms alike are working to develop an equally effective option in the form of pills. The weight loss drug market, projected by Goldman Sachs to reach $130 billion by 2030, represents a significant opportunity for drugmakers. While several oral weight loss therapies have been approved by the US Food and Drug Administration, none are GLP-1 agonists.